pharma · COVID-19 · Hepatitis C · AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
- Founded
- 2014
- Employees
- 57
- Programs
- 37
- Drugs
- 29
- Patents
- 35
Atea Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Atea Pharmaceuticals.
Atea Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AT-527
Atea Pharmaceuticals
COVID-19
2 trials -
AT-527
Atea Pharmaceuticals
Hepatitis C
1 trial -
AT-752
Atea Pharmaceuticals
Dengue Fever
1 trial -
AT-777
Atea Pharmaceuticals
Hepatitis C
1 trial -
Bemnifosbuvir
Atea Pharmaceuticals
Chronic Hepatitis C Virus
1 trial -
GHB11L1
Atea Pharmaceuticals
Influenza, Human
1 trial -
GHB16L2
Atea Pharmaceuticals
Influenza, Human
1 trial
Frequently asked questions
How many clinical projects does Atea Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.